Johnson & Johnson (NYSE:JNJ) Shares Bought by Buffington Mohr McNeal

Posted by Defense World Staff on Oct 16th, 2023

Buffington Mohr McNeal lifted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,843 shares of the company’s stock after buying an additional 252 shares during the quarter. Buffington Mohr McNeal’s holdings in Johnson & Johnson were worth $1,464,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.4% in the 1st quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after purchasing an additional 2,688,798 shares during the period. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Johnson & Johnson by 1.6% in the first quarter. Geode Capital Management LLC now owns 48,707,500 shares of the company’s stock valued at $7,532,525,000 after purchasing an additional 748,917 shares during the period. Morgan Stanley raised its position in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Finally, Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $4,609,399,000. 68.40% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on JNJ shares. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Royal Bank of Canada began coverage on shares of Johnson & Johnson in a report on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 target price on the stock. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 10th. Finally, Atlantic Securities boosted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $171.00.

Read Our Latest Stock Analysis on Johnson & Johnson

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.3 %

Shares of NYSE JNJ opened at $156.85 on Monday. The firm’s 50 day moving average price is $163.10 and its 200 day moving average price is $162.57. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $407.65 billion, a P/E ratio of 31.75, a price-to-earnings-growth ratio of 3.21 and a beta of 0.55. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.59 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.